SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas
Recruiting · NCT06544720 · Interventional (participants receive a specific treatment) · Lead sponsor: The Affiliated Hospital of Qingdao University
View the official record on ClinicalTrials.gov →Interventions studied
SCG142 TCR-T cells
What this trial is about
A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Greater than or equal to 18 years of age
- HPV associated carcinomas
- Patients must have at least one measurable lesion defined by RECIST 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Key
Exclusion criteria
- Active or uncontrollable infections or other active major medical illnesses of the cardiovascular, respiratory.
- Patients with active autoimmune diseases.
- Patient has a known active Hepatitis B or Hepatitis C.
- Other severe medical conditions that may limit subject\'s participation in this trial.
Where it is running
1 location listed.
- The affiliated hosptial of qingdao university - Qingdao, Shandong, China